Mineralys In Hypertension: Upcoming Catalysts And Strong Positioning

I covered Mineralys (NASDAQ: MLYS ) in April last year. It had a few things going that got me interested: It was a new IPO, had just published positive phase 2 data, and it had a strong board of directors. The stock took a deep About the TPT service Thanks for reading. At the Total Pharma Tracker, we offer the following :- ing Balance (millior Projected American Shared Revenue Backlog $250$213 $200$150 $106$104 $101$100 $50$0 12/31/21 12/31/22 12/31/23 5/10/24 (projected*) Ending Balance Date *This cha ...